Last updated on

Journal of Clinical Oncology
Research Hotspot & Journal Scope - inhibitor


Journal of Clinical Oncology - DOI: 10.1200/JCO.2019.37.15_SUPPL.5005
TOPARP-B: A phase II randomized trial of the poly(ADP)-ribose polymerase (PARP) inhibitor olaparib for metastatic castration resistant prostate cancers (mCRPC) with DNA damage repair (DDR) alterations

Joaquin Mateo · Nuria Porta · U. McGovern · Tony Elliott · Robert Jones · Isabel Syndikus · Christy Ralph · Suneil Jain · Mohini Varughese · O. Parikh · Simon J. Crabb · Susana Miranda · George Seed · Claudia Bertan · Aude Espinasse · Peter Chatfield · Diletta Bianchini · Emma Hall · Suzanne Carreira · Johann S. de Bono ·

Medicine
PDF
Journal of Clinical Oncology - DOI: 10.1200/JCO.2019.37.15_SUPPL.6018
Activity and tolerability of BLU-667, a highly potent and selective RET inhibitor, in patients with advanced RET-altered thyroid cancers.

Matthew H. Taylor · Justin F. Gainor · Mimi I-Nan Hu · Viola W. Zhu · Gilberto Lopes · Sophie Leboulleux · Marcia S. Brose · Martin Schuler · Daniel W. Bowles · Dong-Wan Kim · Christina S. Baik · Elena Garralda · Chia-Chi Lin · Douglas Adkins · Debashis Sarker · Giuseppe Curigliano · Hui Zhang · Corinne Clifford · Christopher D. Turner · Vivek Subbiah ·

Medicine
PDF
Journal of Clinical Oncology - DOI: 10.1200/JCO.2019.37.15_SUPPL.1005
Capivasertib (AZD5363) plus fulvestrant versus placebo plus fulvestrant after relapse or progression on an aromatase inhibitor in metastatic ER-positive breast cancer (FAKTION): A randomized, double-blind, placebo-controlled, phase II trial.

Robert Hugh Jones · Margherita Carucci · Angela C. Casbard · Rachel Butler · Fouad S Alchami · Catherine Jane Bale · Pavel Bezecny · Johnathan Joffe · Sarah Moon · Chris Twelves · Ramachandran Venkitaraman · Simon Waters · Sacha J Howell ·

Medicine
PDF
Journal of Clinical Oncology - DOI: 10.1200/JCO.2019.37.7_SUPPL.549
CB-839, a glutaminase inhibitor, in combination with cabozantinib in patients with clear cell and papillary metastatic renal cell cancer (mRCC): Results of a phase I study.

Funda Meric-Bernstam · Richard J. Lee · Bradley Curtis Carthon · Othon Iliopoulos · James W. Mier · Manish R. Patel · Nizar M. Tannir · Taofeek K. Owonikoko · Naomi B. Haas · Martin H. Voss · James J. Harding · Ramaprasad Srinivasan · Geoffrey I. Shapiro · Melinda L. Telli · Pamela N. Munster · Richard D. Carvajal · Yonchu Jenkins · Samuel H. Whiting · Johanna C. Bendell · Todd Michael Bauer ·

Medicine
PDF
Journal of Clinical Oncology - DOI: 10.1200/JCO.2019.37.15_SUPPL.6008
Checkpoint inhibitors assessment in oropharynx cancer (CIAO): Safety and interim results.

Renata Ferrarotto · Diana Bell · M. Laura Rubin · Jiun-Kae Jack Lee · Jason Michael Johnson · Ryan P. Goepfert · Jack Phan · Yasir Elamin · Jeffrey N. Myers · Amy Clark Hessel · Faye M. Johnson · Maura L. Gillison · Andrew G. Sikora · Bonnie S. Glisson · Neil D. Gross ·

Medicine
PDF

A strategy towards a designed multiple ligand of MET and WNT signaling is pursued based on the two hetero biaryl systems present in both the MET inhibitor tepotinib and WNT signaling inhibitor TC-E 5001.

Towards dual inhibitors of the MET kinase and WNT signaling pathway; design, synthesis and biological evaluation [10.1039/c9ra08954c]


Targeting the immune checkpoints cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) and programmed death 1 (PD-1) with inhibitory antibodies has demonstrated effective and durable antitumor activity in subgroups of patients with cancer.

Endocrine Toxicity of Cancer Immunotherapy Targeting Immune Checkpoints. [10.1210/er.2018-00006]


The suitable shale inhibitors must not only efficiently diminish the clay hydration swelling but also fulfill the progressively rigorous environmental regulations, even though staying cost-efficient.

Advanced developments in shale inhibitors for oil production with low environmental footprints – A review [10.1016/J.FUEL.2019.03.006]


Imaging showed left kidney hemorrhage, his labs were significant for a prolonged partial thromboplastin time (PTT), and subsequent tests revealed low factor VIII levels and high factor VIII inhibitor levels, which led to the diagnosis of acquired hemophilia A in the patient.

Acquired Hemophilia A: A Rare but Potentially Fatal Bleeding Disorder [10.7759/cureus.5442]


gondii infection of primary monocytes, and inhibiting Syk with the pharmacological inhibitors R406 or entospletinib, or genetic ablation of Syk in THP-1 cells, reduced IL-1β release.

Toxoplasma gondii activates a Syk-CARD9-NF-κB signaling axis and gasdermin D-independent release of IL-1β during infection of primary human monocytes [10.1371/journal.ppat.1007923]


Highly Related Keywords from inhibitor

Research Hotspot

Journal of Clinical Oncology

Research Hotspot
Journal of Clinical Oncology Related Journals

Popular Journals